Institutional Investors Increase Stakes in Exelixis Stock
What happened
According to a filing with the Securities and Exchange Commission, several institutional investors increased their stake in Exelixis during the third quarter. Profund Advisors LLC increased its holdings by 36.0%, now owning 42,521 shares valued at $2,484,000. Other firms, including Private Client Services LLC and Sumitomo Mitsui Trust Group Inc., also raised their positions in the biotechnology company's stock. Brindle & Bay Financial Advisors LLC and Soltis Investment Advisors LLC also lifted their positions during the quarter.
From themarketsdaily.com
Why it matters
The increase in institutional ownership reflects significant capital inflow into Exelixis. This trend in large-scale purchasing can influence market sentiment and investor confidence in the company's future performance.
From themarketsdaily.com
Who's involved
- ExelixisAmerican biotechnology company whose stock is being purchased by institutional investors.
- Securities and Exchange CommissionGovernment agency that tracks mandatory institutional filings for Exelixis.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- TD CowenSpeculative
Investment banks might adjust their rating recommendations based on the disclosure of institutional selling and buying.
- CitigroupSpeculative
Investment banks might adjust their rating recommendations based on the disclosure of institutional selling and buying.
- Leerink partnersSpeculative
Investment banks might adjust their rating recommendations based on the disclosure of institutional selling and buying.
Keep exploring
The entities involved
-
Mary Beckerle
American biologist and businessperson, CEO of Huntsman Cancer Institute at the University of Utah and corporate director at Johnson and Johnson
Nothing else this week.
-
Exelixis
American biotechnology company
-
Securities and Exchange Commission
government agency of the Philippines